| 瑞舒伐他汀对糖尿病心肌病患者脑钠肽和超敏 C反应蛋白的影响 |
| |
| 引用本文： | 周磊,严金川,于文敏.瑞舒伐他汀对糖尿病心肌病患者脑钠肽和超敏 C反应蛋白的影响[J].安徽医药,2014,0(12):2363-2365. |
| |
| 作者姓名： | 周磊 严金川 于文敏 |
| |
| 作者单位： | 江苏大学附属金坛医院,江苏金坛,213200;江苏大学附属医院,江苏镇江,212001 |
| |
| 摘 要： | 目的：探讨瑞舒伐他汀对糖尿病心肌病患者脑钠肽（ BNP）和超敏C反应蛋白（ hs-CRP）的影响。方法将60例糖尿病心肌病患者随机分为对照组（30例）和治疗组（30例）。对照组在治疗过程中予严格控制血糖并给予抗心衰规范化治疗；治疗组在对照组治疗基础上加用瑞舒伐他汀（10 mg · d-1）治疗。所有患者均在治疗前及治疗后12周测定左室舒张末期内径（LVDd）、左室射血分数（LVEF）、血清低密度脂蛋白（LDL-C）及血浆脑钠肽前体检氨基端片段（NT-proBNP，简称BNP）和血清超敏C反应蛋白（ hs-CRP）。结果12周后所有患者LVDd、LVEF治疗前后无统计学差异，两组间降幅差异亦无统计学意义LVDd：（-0．7±2．2） vs （-1．5±1．5），P＝0．779；LVEF：（0．6±1．4） vs （0．3±1．5），P＝0．589]。治疗组较对照组的LDL-C、BNP及hs-CRP的降低幅度均有显著增加LDL-C：（-1．77±0．29） vs （0．04±0．24），P＝0．000；BNP：（-360．5±414．0） vs （-15．1±217．3），P＝0．008；hs-CRP：（-0．84±0．65） vs （-0．17±0．40），P＝0．002]。结论瑞舒伐他汀钙能显著降低糖尿病心肌病患者的炎症介质及脑钠肽水平，提示该药改善其心功能。
|
| 关 键 词： | 糖尿病心肌病 瑞舒伐他汀 超敏C反应蛋白 脑钠肽 |
Effects of rosuvastatin on brain natriuretic peptide and hypersensitive C-reactive protein in patients with diabetic cardiomyopathies |
| |
| ZHOU Lei,YAN Jin-chuan,YU wen-min.Effects of rosuvastatin on brain natriuretic peptide and hypersensitive C-reactive protein in patients with diabetic cardiomyopathies[J].Anhui Medical and Pharmaceutical Journal,2014,0(12):2363-2365. |
| |
| Authors: | ZHOU Lei YAN Jin-chuan YU wen-min |
| |
| Institution: | ZHOU Lei;YAN Jin-chuan;YU wen-min;The Affiliated Jintan Hospital of Jiangsu University;The Affiliated Hospital of Jiangsu University; |
| |
| Abstract: | Objective To investigate the effect of rosuvastatin on brain natriuretic peptide and hypersensitive C -reactive protein in pa-tients with diabetic cardiomyopathies .Methods Sixty patients with diabetic cardiomyopathies were randomized into 2 groups：the con-trol group（n=30） and the intervention group（n=30）.Management of blood glucose and heart failure was performed in the 2 groups, with rosuvastatin（10 mg· d-1 ） added to the patients in the treatment group .LVDd,LVEF,LDL-C,BNP and hs-CRP measurement was performed in every patient before and 12 weeks after initiation of the study .Results After 12 weeks of treatment ,compared to the con-trol group,the levels of LDL-C,BNP and hs-CRP were significantly decreased in treatment group LDL-C：（-1.77 ±0.29） vs （0.04 ±0.24）,P=0.000;BNP：（-360.5 ±414.0） vs （-15.1 ±217.3）,P=0.008;hs-CRP：（-0.84 ±0.65） vs （ -0.17 ±0.40）, P=0.002].However,there were no significant differences in the LVDd and LVEF between control and treatment group ,LVDd：（-0.7 ±2.2） vs （-1.5 ±1.5）,P=0.779;LVEF：（0.6 ±1.4） vs （0.3 ±1.5）,P=0.589].Conclusions Rosuvastatin signifi-cantly reduces the inflammatory mediators and brain natriuretic peptide levels in patients with diabetic cardiomyopathies ,which indi-cates that this medicine probably improves the heart function of the patients . |
| |
| Keywords: | diabetic cardiomyopathies rosuvastatin hypersensitive C-reactive protein brain natriuretic peptide |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
